Kimberly G Blumenthal1, Kenneth H Lai2, Mingshu Huang3, Zachary S Wallace4, Paige G Wickner5, Li Zhou6. 1. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Mass. Electronic address: kblumenthal1@partners.org. 2. Partners HealthCare System, Boston, Mass. 3. Biostatistics Center, Massachusetts General Hospital, Boston, Mass. 4. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. 5. Harvard Medical School, Boston, Mass; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass. 6. Harvard Medical School, Boston, Mass; Partners eCare, Partners HealthCare System, Boston, Mass; Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Abstract
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used medications in the United States. NSAID use can be limited by adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs). OBJECTIVE: We aimed to use electronic health record data to determine the incidence and predictors of HSRs to prescription NSAIDs. METHODS: We performed a retrospective cohort study of all adult outpatients in a large health care system prescribed diclofenac, indomethacin, nabumetone, or piroxicam between January 1, 2004, and September 30, 2012. The primary outcome was an ADR or HSR attributed to the prescribed NSAID within 1 year of prescription, determined from a longitudinal allergy database. We used natural language processing to classify known ADRs as either HSRs or side effects. Multivariable logistic regression models were used to identify independent risk factors for NSAID HSRs. RESULTS: Of 62,719 patients prescribed NSAIDs, 1,035 (1.7%) had an ADR, of which 189 (18.3%) were HSRs. Multivariable regression analysis identified that patients with prior drug HSR history (odds ratio [OR] 1.8 [95% CI 1.3, 2.5]), female sex (OR 1.8 [95% CI 1.3, 2.4]), autoimmune disease (OR 1.7 [95% CI 1.1, 2.7]), and those prescribed the maximum standing NSAID dose (OR 1.5 [95% CI 1.1, 2.0]) had increased odds of NSAID HSR. CONCLUSIONS: NSAID therapeutic use can be limited by ADRs; about 1 in 5 NSAID ADRs is an HSR. Both patient and drug factors contribute to HSR risk and are important to guide patient counseling.
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used medications in the United States. NSAID use can be limited by adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs). OBJECTIVE: We aimed to use electronic health record data to determine the incidence and predictors of HSRs to prescription NSAIDs. METHODS: We performed a retrospective cohort study of all adult outpatients in a large health care system prescribed diclofenac, indomethacin, nabumetone, or piroxicam between January 1, 2004, and September 30, 2012. The primary outcome was an ADR or HSR attributed to the prescribed NSAID within 1 year of prescription, determined from a longitudinal allergy database. We used natural language processing to classify known ADRs as either HSRs or side effects. Multivariable logistic regression models were used to identify independent risk factors for NSAID HSRs. RESULTS: Of 62,719 patients prescribed NSAIDs, 1,035 (1.7%) had an ADR, of which 189 (18.3%) were HSRs. Multivariable regression analysis identified that patients with prior drug HSR history (odds ratio [OR] 1.8 [95% CI 1.3, 2.5]), female sex (OR 1.8 [95% CI 1.3, 2.4]), autoimmune disease (OR 1.7 [95% CI 1.1, 2.7]), and those prescribed the maximum standing NSAID dose (OR 1.5 [95% CI 1.1, 2.0]) had increased odds of NSAID HSR. CONCLUSIONS: NSAID therapeutic use can be limited by ADRs; about 1 in 5 NSAID ADRs is an HSR. Both patient and drug factors contribute to HSR risk and are important to guide patient counseling.
Authors: E Faria; J Rodrigues-Cernadas; A Gaspar; C Botelho; E Castro; A Lopes; E Gomes; D Malheiro; S Cadinha; S Campina-Costa; M Neto; N Sousa; R Rodrigues-Alves; A Romeira; J Caiado; M Morais-Almeida Journal: J Investig Allergol Clin Immunol Date: 2014 Impact factor: 4.333
Authors: M Sánchez-Borges; F Caballero-Fonseca; A Capriles-Hulett; L González-Aveledo Journal: J Eur Acad Dermatol Venereol Date: 2014-09-29 Impact factor: 6.166
Authors: M L Kowalski; R Asero; S Bavbek; M Blanca; N Blanca-Lopez; G Bochenek; K Brockow; P Campo; G Celik; J Cernadas; G Cortellini; E Gomes; E Niżankowska-Mogilnicka; A Romano; A Szczeklik; S Testi; M J Torres; S Wöhrl; J Makowska Journal: Allergy Date: 2013-10-05 Impact factor: 13.146
Authors: Aafke R Koffeman; Amanda R Van Buul; Vera E Valkhoff; Geert W 't Jong; Patrick J E Bindels; Miriam C J M Sturkenboom; Johan Van der Lei; Pim A J Luijsterburg; Sita M A Bierma-Zeinstra Journal: Scand J Prim Health Care Date: 2015-07-22 Impact factor: 2.581
Authors: Joseph M Plasek; Foster R Goss; Kenneth H Lai; Jason J Lau; Diane L Seger; Kimberly G Blumenthal; Paige G Wickner; Sarah P Slight; Frank Y Chang; Maxim Topaz; David W Bates; Li Zhou Journal: J Am Med Inform Assoc Date: 2015-09-17 Impact factor: 4.497
Authors: M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson Journal: Br J Clin Pharmacol Date: 1993-04 Impact factor: 4.335
Authors: Neil Dhopeshwarkar; Aziz Sheikh; Raymond Doan; Maxim Topaz; David W Bates; Kimberly G Blumenthal; Li Zhou Journal: J Allergy Clin Immunol Pract Date: 2018-06-30
Authors: Kimberly G Blumenthal; Anna R Wolfson; Yu Li; Claire M Seguin; Neelam A Phadke; Aleena Banerji; Elizabeth Mort Journal: J Patient Saf Date: 2021-12-01 Impact factor: 2.844